Molecular Basis and Treatment of Cardiac Arrhythmias

心律失常的分子基础和治疗

• 批准号: 7918945
• 负责人: SUI RONG WAYNE CHEN
• 金额: $ 35.21万
• 依托单位: RUSH UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-21 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7918945
• 关键词: Adrenergic beta-Antagonists; Adverse effects; Animals; Anti-Arrhythmia Agents; Arrhythmia; Cardiac; Cells; Clinical Trials; Data; Defect; Development; Electrocardiogram; Exhibits; Heart failure; Image; Incidence; Lead; Link; Molecular; Mutant Strains Mice; Mutation; Pathogenesis; Patients; Pharmaceutical Preparations; Prevention; Process; Risk; RyR2; Ryanodine Receptor Calcium Release Channel; Ryanodine Receptors; Site-Directed Mutagenesis; Stress; Sudden Death; Testing; Therapeutic; Ventricular Arrhythmia; Work; analog; base; carvedilol; design; improved; inhibitor/antagonist; insight; mortality; novel; prevent; prototype; public health relevance; sensor; sudden cardiac death

DESCRIPTION (provided by applicant): A major cause of sudden death in patients with heart failure (HF) is ventricular arrhythmia. Disappointingly, large clinical trials have recently demonstrated that most of the anti-arrhythmic drugs have little or no survival benefits. Surprisingly, ¿-blockers, once thought to be dangerous and contraindicated for patients with HF, have consistently been shown to reduce the risk of sudden death. However, the molecular mechanisms underlying ¿-blockers' survival benefits are unknown. The overall objective of this proposal is to understand the beneficial effects of ¿-blockers and to develop novel anti-arrhythmic agents. It is well known that spontaneous Ca2+ release, also known as store-overload-induced-Ca2+-release (SOICR), can cause delayed afterdepolarizations (DADs), which in turn can trigger arrhythmias. Importantly, enhanced SOICR activity and DAD-associated ventricular arrhythmias are common in HF and in cardiac ryanodine receptor (RyR2)-associated ventricular arrhythmias. Hypotheses: the beneficial effects of ¿-blockers are, in part, attributable to SOICR inhibition, and that SOICR inhibitors are effective in suppressing cardiac arrhythmias. Three specific aims are proposed. 1. To Assess the Impact of Different ¿-blockers on Spontaneous Ca2+ Release or SOICR and RyR2-Associated Arrhythmias. The impact of a number of ¿-blockers on SOICR, the activity of RyR2, and stress-induced ventricular arrhythmias will be determined using various approaches. 2. To Design, Synthesize, and Characterize Novel Carvedilol Analogues for Suppressing Arrhythmias. Our preliminary data demonstrate that carvedilol is uniquely effective among ¿- blockers in suppressing SOICR. To improve its efficacy and to produce a novel class of anti-arrhythmic agents, a number of carvedilol derivatives will be synthesized in order to reduce or diminish its ¿-blocking activity, while retaining or increasing its SOICR inhibition. 3. To Understand the Molecular Basis of SOICR. Site-directed mutagenesis in conjunction with single channel analysis will be used to test our hypothesis that SOICR is governed by a luminal Ca2+ sensor located within the RyR2 channel pore. Significance: These proposed studies will not only shed novel mechanistic insight into the molecular basis of cardiac arrhythmias, but also lead to the development of a new and promising class of anti-arrhythmic agents, and have direct implications for the prevention and treatment of cardiac arrhythmias. PUBLIC HEALTH RELEVANCE: A major cause of sudden death in patients with heart failure is ventricular arrhythmia. Consequently, a variety of anti-arrhythmic therapies have been developed over the past 3-4 decades. However, recent large clinical trials have demonstrated that the majority of these drugs have little or no survival benefits. Beta-blockers have consistently been shown to reduce the risk of sudden death. However, the molecular mechanisms underlying beta-blockers' survival benefits are unknown. This proposal seeks to identify the mechanisms responsible for beta-blockers' beneficial effects, and to develop novel anti-arrhythmic therapies that target these mechanisms. These proposed studies will not only shed novel mechanistic insight into the molecular basis of cardiac arrhythmias, but also lead to the development of a new and promising class of anti-arrhythmic agents, and have direct implications for the prevention and treatment of cardiac arrhythmias.

描述（由申请人提供）：心力衰竭（HF）患者猝死的主要原因是室性心律失常。令人不安的是，最近的大型临床试验表明，大多数抗疟疾药物几乎没有或没有生存益处。令人惊讶的是，β受体阻滞剂曾被认为是危险的，对HF患者是禁忌的，但一直被证明可以降低猝死的风险。然而，阻断剂的生存益处的分子机制尚不清楚。该提案的总体目标是了解β-受体阻滞剂的有益作用，并开发新型抗肿瘤药物。众所周知，自发性Ca 2+释放，也称为钙库超负荷诱导的Ca 2+释放（SOICR），可引起延迟后除极（DAD），进而可触发心律失常。重要的是，增强的SOICR活性和DAD相关的室性心律失常在HF和心脏兰尼碱受体（RyR 2）相关的室性心律失常中很常见。假设条件：的有利影响，β-受体阻滞剂部分归因于SOICR抑制，并且SOICR抑制剂有效抑制心律失常。提出了三个具体目标。1.评估不同受体阻滞剂对自发性Ca 2+释放或SOICR和RyR 2相关心律失常的影响。将使用各种方法确定许多β-受体阻滞剂对SOICR、RyR 2活性和应激诱导的室性心律失常的影响。2.设计、合成和表征用于抑制心律失常的新型卡维地洛类似物。我们的初步数据表明，卡维地洛是唯一有效的抑制SOICR的ω-阻滞剂。为了提高其功效并产生一类新的抗肿瘤剂，将合成许多卡维地洛衍生物以降低或减少其β-阻断活性，同时保持或增加其SOICR抑制。3.了解SOICR的分子基础。结合单通道分析的定点诱变将被用来测试我们的假设，SOICR是由位于RyR 2通道孔内的管腔Ca 2+传感器。重要性：这些研究不仅将为心律失常的分子基础提供新的机制见解，而且还将导致一类新的和有前途的抗心律失常药物的开发，并对心律失常的预防和治疗具有直接意义。公共卫生相关性：心力衰竭患者猝死的主要原因是室性心律失常。因此，在过去的3- 40年中，已经开发了各种抗疟疾疗法。然而，最近的大型临床试验表明，这些药物中的大多数几乎没有或没有生存益处。β受体阻滞剂一直被证明可以降低猝死的风险。然而，β受体阻滞剂的生存益处的分子机制尚不清楚。该提案旨在确定负责β受体阻滞剂有益作用的机制，并开发针对这些机制的新型抗肿瘤疗法。这些研究不仅将为心律失常的分子基础提供新的机制见解，而且还将导致一类新的和有前途的抗心律失常药物的开发，并对心律失常的预防和治疗具有直接意义。